The Effectiveness of Myo-Inositol and D-Chiro Inositol Treatment in Type 2 Diabetes

International Journal of Endocrinology

Volumn 2016, Issue , 2016, Pages

  Pintaudi, Basilio ^a   Di Vieste, Giacoma ^b   Bonomo, Matteo ^a  

^a OSPEDALE NIGUARDA CA GRANDA   (Italy)

^b Department of Ophthalmology   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CHIRO INOSITOL; CHOLESTEROL; FOLIC ACID; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INOSITOL; INOSITOL DERIVATIVE; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; ORAL ANTIDIABETIC AGENT; UNCLASSIFIED DRUG;

ABSENCE OF SIDE EFFECTS; ADD ON THERAPY; ADULT; ARTICLE; BLOOD PRESSURE; BODY MASS; CLINICAL ARTICLE; COMORBIDITY; CONTROLLED STUDY; DISEASE DURATION; DRUG EFFICACY; DRUG SAFETY; FEMALE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEMOGLOBIN BLOOD LEVEL; HUMAN; MALE; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; PILOT STUDY;

EID: 84993982661     PISSN: 16878337     EISSN: 16878345     Source Type: Journal    
DOI: 10.1155/2016/9132052     Document Type: Article

References (31)

1. Y. Pak, L. C. Huang, K. J. Lilley, and J. Larner, "In vivo conversion of [3H]myoinositol to [3H]chiroinositol in rat tissues," The Journal of Biological Chemistry, vol. 267, no. 24, pp. 16904-16910, 1992.
2. H. K. Ortmeyer, L. C. Huang, L. Zhang, B. C. Hansen, and J. Larner, "Chiroinositol deficiency and insulin resistance. II. Acute effects of D-chiroinositol administration in streptozotocin-diabetic rats, normal rats given a glucose load, and spontaneously insulin-resistant rhesus monkeys," Endocrinology, vol. 132, no. 2, pp. 646-651, 1993.
3. H. K. Ortmeyer, "Dietary myoinositol results in lower urine glucose and in lower postprandial plasma glucose in obese insulin resistant rhesus monkeys," Obesity Research, vol. 4, no. 6, pp. 569-575, 1996.
4. M. L. Croze and C. O. Soulage, "Potential role and therapeutic interests of myo-inositol in metabolic diseases," Biochimie, vol. 95, no. 10, pp. 1811-1827, 2013.
5. J. Larner, "D-chiro-inositol-its functional role in insulin action and its deficit in insulin resistance," International Journal of Experimental Diabetes Research, vol. 3, no. 1, pp. 47-60, 2002.
6. V. Unfer and G. Porcaro, "Updates on themyo-inositol plusDchiro-inositol combined therapy in polycystic ovary syndrome," Expert Review of Clinical Pharmacology, vol. 7, no. 5, pp. 623-631, 2014.
7. S. Dinicola, T. T. Y. Chiu, V. Unfer, G. Carlomagno, and M. Bizzarri, "The rationale of the myo-inositol and D-chiroinositol combined treatment for polycystic ovary syndrome," Journal of Clinical Pharmacology, vol. 54, pp. 1079-1092, 2014.
8. V. Unfer, G. Carlomagno, G. Dante, and F. Facchinetti, "Effects of myo-inositol in women with PCOS: a systematic review of randomized controlled trials," Gynecological Endocrinology, vol. 28, no. 7, pp. 509-515, 2012.
9. D. Giordano, F. Corrado, A. Santamaria et al., "Effects of myo-inositol supplementation in postmenopausal women with metabolic syndrome: a perspective, randomized, placebocontrolled study," Menopause, vol. 18, no. 1, pp. 102-104, 2011.
10. A. Santamaria, D. Giordano, F. Corrado et al., "One-year effects of myo-inositol supplementation in postmenopausal women with metabolic syndrome," Climacteric, vol. 15, no. 5, pp. 490-495, 2012.
11. T. J. Crawford, C. A. Crowther, J. Alsweiler, and J. Brown, "Antenatal dietary supplementation with myo-inositol in women during pregnancy for preventing gestational diabetes," The Cochrane Database of Systematic Reviews, no. 12, Article ID CD011507, 2015.
12. A. Santamaria, A. Di Benedetto, E. Petrella et al., "Myo-inositol may prevent gestational diabetes onset in overweight women: a randomized, controlled trial," Journal of Maternal-Fetal and Neonatal Medicine, vol. 23, pp. 1-4, 2015.
13. R. D'Anna, A. Di Benedetto, A. Scilipoti et al., "Myo-inositol supplementation for prevention of gestational diabetes in obese pregnant women: a randomized controlled trial," Obstetrics & Gynecology, vol. 126, no. 2, pp. 310-315, 2015.
14. R. D'Anna, A. Scilipoti, D. Giordano et al., "Myo-inositol supplementation and onset of gestational diabetes mellitus in pregnant women with a family history of type 2 diabetes: a prospective, randomized, placebo-controlled study," Diabetes Care, vol. 36, no. 4, pp. 854-857, 2013.
15. F. Corrado, R. D'Anna, G. di Vieste et al., "The effect of myoinositol supplementation on insulin resistance in patients with gestational diabetes," Diabetic Medicine, vol. 28, no. 8, pp. 972-975, 2011.
16. V. Lubin, R. Shojai, P. Darmon, and E. Cosson, "A pilot study of gestational diabetes mellitus not controlled by diet alone: firstline medical treatment with myoinositol may limit the need for insulin," Diabetes & Metabolism, vol. 42, no. 3, pp. 192-195, 2016.
17. V. T. Samuel and G. I. Shulman, "Mechanisms for insulin resistance: common threads and missing links," Cell, vol. 148, no. 5, pp. 852-871, 2012.
18. I.W. Campbell and H. C. S. Howlett, "Worldwide experience of metformin as an effective glucose-lowering agent: a metaanalysis," Diabetes/Metabolism Reviews, vol. 11, supplement 1, pp. S57-S62, 1995.
19. K. Johansen, "Efficacy of metformin in the treatment of NIDDM: meta-analysis," Diabetes Care, vol. 22, no. 1, pp. 33-37, 1999.
20. R.C. Turner, C. A. Cull, V. Frighi, and R. R. Holman, "Glycemic controlwith diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group," JAMA, vol. 281, no. 21, pp. 2005-2012, 1999.
21. D. M. Nathan, J. B. Buse, M. B. Davidson et al., "Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes," Diabetes Care, vol. 32, no. 1, pp. 193-203, 2009.
22. J. Perk, G. DeBacker, H. Gohlke et al., "European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts)," European Heart Journal, vol. 33, no. 13, pp. 1635-1701, 2012.
23. "Standards of medical care in diabetes-2016," Diabetes Care, vol. 39, supplement 1, 2016.
24. T.-H. Sun, D. B. Heimark, T. Nguygen, J. L. Nadler, and J. Larner, "Both myo-inositol to chiro-inositol epimerase activities and chiro-inositol to myo-inositol ratios are decreased in tissues of GK type 2 diabetic rats compared to Wistar controls," Biochemical and Biophysical Research Communications, vol. 293, no. 3, pp. 1092-1098, 2002.
25. International Diabetes Federation, 2015, http://www.diabetesatlas.org.
26. M. Shichiri, H. Kishikawa, Y. Ohkubo, and N. Wake, "Longterm results of the Kumamoto Study on optimal diabetes control in type 2 diabetic patients," Diabetes Care, vol. 23, supplement 2, pp. B21-B29, 2000.
27. R. R. Holman, S. K. Paul, M.A. Bethel, D. R. Matthews, and H. A. W. Neil, "10-Year follow-up of intensive glucose control in type 2 diabetes," The New England Journal of Medicine, vol. 359, no. 15, pp. 1577-1589, 2008.
28. M. Monami, C. Lamanna, N. Marchionni, and E. Mannucci, "Comparison of different drugs as add-on treatments to metformin in type 2 diabetes: a meta-analysis," Diabetes Research and Clinical Practice, vol. 79, no. 2, pp. 196-203, 2008.
29. S.-C. Liu, Y.-K. Tu, M.-N. Chien, and K.-L. Chien, "Effect of antidiabetic agents added to metformin on glycaemic control, hypoglycaemia and weight change in patients with type 2 diabetes: a network meta-analysis," Diabetes, Obesity and Metabolism, vol. 14, no. 9, pp. 810-820, 2012.
30. P. Sudchada, S. Saokaew, S. Sridetch, S. Incampa, S. Jaiyen, and W. Khaithong, "Effect of folic acid supplementation on plasma total homocysteine levels and glycemic control in patients with type 2 diabetes: a systematic reviewand meta-analysis," Diabetes Research and Clinical Practice, vol. 98, no. 1, pp. 151-158, 2012.
31. R. Agostini, F. Rossi, and R. Pajalich, "Myoinositol/folic acid combination for the treatment of erectile dysfunction in type 2 diabetes men: a double-blind, randomized, placebo-controlled study," European Review for Medical and Pharmacological Sciences, vol. 10, no. 5, pp. 247-250, 2006.